NCCN Updates Guidelines for Lung Cancer Screening
The National Comprehensive Cancer Network (NCCN) has published updates to their clinical practice guidelines for lung cancer screening, including updates to risk assessment, risk status, and screening findings.
For the section on risk assessment (LCS-1), a bullet was added for functional status to support curative intent treatment. Group 1 and Group 2 were added as subheadings under high-risk in the risk status section (LCS-1).
For follow-up or annual screening LDCT in the section for screening findings (LCS-2), content was changed from the same recommendations after initial screening to the same recommendations from LCS-6.
For follow-up screening findings (LCS-7), under solid endobronchial nodule, “LDCT in 1 month” was changed to “LDCT ≤ 1 month.” Also, the footnote, "Criteria for suspicion of malignancy: hypermetabolism greater than the adjacent mediastinal blood pool, regardless of absolute SUV," was removed. The same footnote was removed from LCS-4, LCS-7, and LCS-8.
For evaluation of screening findings (LCS-7), growing is defined as greater than 1.5 mm. In evaluation of screening findings (LCS-8), growing is defined as greater than 1.5 mm in solid components.
In the section for follow-up of screening findings (LCS-9) of newly identified non-solid nodules ≥ 20 mm, recommendations were changed from “Annual LDCT or consider biopsy or surgical excision” to “LDCT in 6 months”.—Janelle Bradley
